Investigator

Maha Hussein

Professor · Northwestern University, Medicine, Division of Hematology Oncology

About

Research Interests

MHMaha Hussein
Papers(1)
Genomic Landscape of …
Collaborators(9)
Mary MulcahyMassimo CristofanilliWilliam GradisharYoung K. ChaeDevalingam MahalingamFiras WehbeJeannine DonahueJyoti PatelLorenzo Gerratana
Institutions(3)
Indiana University Sc…Robert H Lurie Compre…University Of Udine

Papers

Genomic Landscape of Advanced Solid Tumors in Circulating Tumor DNA and Correlation With Tissue Sequencing: A Single Institution's Experience

PURPOSECirculating tumor DNA (ctDNA) has emerged as a promising noninvasive biomarker for baseline characterization and longitudinal monitoring of a tumor throughout disease management. The aim of this study was to evaluate the utility of ctDNA across a wide spectrum of tumor types.METHODSWe retrospectively identified 1,763 patients with advanced cancers who had next-generation sequencing of ctDNA or tumor tissue completed by a designated commercial assay at Northwestern University.RESULTSctDNA identified at least one gene alteration in 90% of patients. The number of detected alterations (NDA) and mutant allele frequency (MAF) of the most frequently mutated genes varied significantly across tumor types, with the highest MAF observed in gastric, colorectal, and breast cancers and the highest NDA observed in colorectal, lung squamous, and ovarian/endometrial cancers. TP53 was the most mutated gene in all tumor types. PIK3CA, ERBB2, BRCA1, and FGFR1 alterations were associated with breast cancer, and ESR1 mutations were exclusively detected in this tumor type. Colorectal cancer was characterized by alterations in KRAS and APC mutations, whereas KRAS, EGFR, PIK3CA, and BRAF mutations were common in lung adenocarcinoma. Concordance between blood and tissue sequencing was notably observed for truncal gene alterations (eg, APC and KRAS), whereas low concordance was often observed in genes associated with treatment resistance mechanisms (eg, RB1 and NF1). Tumor mutational burden (TMB) varied significantly across tumor types, and patients with high MAF or NDA had a significantly higher TMB score with one of the investigated platforms.CONCLUSIONThe study provided new insights into the ctDNA mutational landscape across solid tumors, suggesting new hypotheses-generating data and caveats for future histotype-agnostic workflows integrated with tissue-based biomarkers such as TMB.

411Works
1Papers
9Collaborators
Prostatic NeoplasmsNeoplasm MetastasisBiomarkers, TumorPrognosisCirculating Tumor DNABone NeoplasmsCarcinoma, Neuroendocrine

Positions

2016–

Professor

Northwestern University · Medicine, Division of Hematology Oncology

2006–

Professor

University of Michigan · Internal Medicine and Urology

2002–

Clinical Professor

University of Michigan · Internal Medicine and Urology

2001–

Professor

Wayne State University · Medicine and Oncology

1996–

Associate Professor of Medicine

Wayne State University · Internal Medicine, Division of Hematology/Oncology

1989–

Assistant Professor

Wayne State University · Internal Medicine, Division of Hematology/Oncology

Education

1989

Fellow

Wayne State University · Internal Medicine, Division of Hematology/Oncology

1986

Resident

Wayne State University · Internal Medicine

1984

Intern

Wayne State University · Internal Medicine

1980

MD (MBChB)

University of Baghdad · Medicine